Ned Pagliarulo

Lead Editor at BioPharma Dive

Lead editor @BioPharmaDive

Featured in: Favicon

biopharmadive.com Favicon

utilitydive.com Favicon

healthcaredive.com Favicon

fooddive.com Favicon

supplychaindive.com Favicon

ciodive.com Favicon

k12dive.com Favicon

medtechdive.com Favicon

cfodive.com Favicon

industrydive.com + 8 more

Articles

Trump revives ‘most favored nation’ plan in effort to cut US drug prices

3 days ago | biopharmadive.com | Jonathan Gardner |Ned Pagliarulo

The Trump administration is resurrecting a controversial policy that aims to tamp down some pharmaceutical costs in the U.S. by linking them to prices paid abroad, delivering another jolt to an industry it has already targeted for tariffs.
Novo cuts forecasts as compounded GLP-1s weigh on sales

1 week ago | biopharmadive.com | Ned Pagliarulo

Dive Brief:While revenue and profit rose year-over-year during the first quarter at Novo Nordisk, the Danish drugmaker on Wednesday scaled back its financial forecasts for 2025 due to the impact compounded copies of its popular GLP-1 medicines have had on sales. Net sales and operating profit grew 19% and 22%, respectively, compared to the same period last year, according to earnings statements.
PTC stock slides on new data for Huntington’s drug

1 week ago | biopharmadive.com | Ned Pagliarulo

Dive Brief:Shares in PTC Therapeutics fell by double-digits Monday morning as investors parsed new clinical trial results for an important Huntington’s disease drug the biotechnology company has been developing. Results from the study showed PTC’s drug lowered levels of a target protein associated with Huntington’s, confirming an earlier readout. According to the company, the data also suggested “trends” in benefit on scales designed to assess clinical outcomes.
Pharma downplays tariff threat, even as risks remains unclear

1 week ago | biopharmadive.com | Ned Pagliarulo |Jonathan Gardner

The threat of tariffs on pharmaceuticals imported to the U.S. hasn’t yet pushed drugmakers off course, with many of the largest companies indicating they expect to be able to absorb any impact in the short term. Speaking on earnings calls in recent weeks, pharma executives have, for the most part, told investors their supply chains are flexible enough to mitigate the effects of new levies — for this year, at least.
J&J scores FDA OK for immune drug touted as future blockbuster

2 weeks ago | pharmavoice.com | Ned Pagliarulo

This audio is auto-generated. Please let us know if you have feedback. The FDA on Wednesday approved an antibody drug that developer Johnson & Johnson expects will eventually become one of its top-selling medicines. The drug, which J&J will sell as Imaavy, was cleared by the FDA to treat adults and children 12 years of age or older who have an autoimmune condition known as generalized myasthenia gravis.
J&J secures FDA OK for immune drug touted as future blockbuster

2 weeks ago | biopharmadive.com | Ned Pagliarulo

The Food and Drug Administration on Wednesday approved an antibody drug that developer Johnson & Johnson expects will eventually become one of its top-selling medicines. The drug, which J&J will sell as Imaavy, was cleared by the FDA to treat adults and children 12 years of age or older who have an autoimmune condition known as generalized myasthenia gravis.
J&J secures FDA OK for immune drug touted as future blockbuster

2 weeks ago | yahoo.com | Ned Pagliarulo

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The Food and Drug Administration on Wednesday approved an antibody drug that developer Johnson & Johnson expects will eventually become one of its top-selling medicines.
Pfizer’s Bourla ‘cautiously optimistic’ on looming US pharma tariffs

2 weeks ago | biopharmadive.com | Ned Pagliarulo

Pfizer will maintain its 2025 financial forecasts for now, but warned Tuesday it can’t predict the impact of any tariffs or trade policy changes the Trump administration might impose on the pharmaceutical sector. “While we continue to engage and plan for contingencies, we’re focusing day to day on what we can do to move our business forward,” Pfizer CEO Albert Bourla said in remarks prepared for the company’s earnings call for the first quarter.
Merck KGaA to buy biotech SpringWorks for $3.9B

2 weeks ago | biopharmadive.com | Ned Pagliarulo

Dive Brief:Merck KGaA has agreed to buy biotechnology company SpringWorks Therapeutics, announcing Monday a $3.9 billion deal after months of negotiations over an acquisition. The German pharmaceutical firm will pay $47 per SpringWorks share, a small premium to the stock’s closing price Friday but 17% higher than the $40.28 it closed at on Feb. 7, the last trading day before reports emerged of the companies’ discussions.
Makary seeks to limit industry’s role in FDA advisory panels

3 weeks ago | medtechdive.com | Ned Pagliarulo

The Food and Drug Administration will aim to limit the participation of industry experts in the advisory committees that the agency consults for some regulatory decisions, Martin Makary, the FDA’s new commissioner, announced Thursday. Advisory committees, which the FDA typically convenes for additional input on high-profile reviews or thorny clinical and regulatory issues, regularly include an industry representative alongside a dozen or so independent experts.